Faye Hsieh

发表

Critical review of p38 MAP kinase inhibitors: a bioanalytical perspective.

C. James, P. Wong, Faye Hsieh, 2012, Bioanalysis.

Simultaneous determination of a p38 MAP kinase inhibitor and its amide hydrolyzed metabolite in Cynomolgus monkey plasma by LC-MS/MS, and its application to a toxicokinetic study.

A. Akrami, C. James, P. Wong, 2011, Journal of pharmaceutical and biomedical analysis.

HIGH ABSORPTION BUT VERY LOW BIOAVAILABILITY OF ORAL RESVERATROL IN HUMANS

T. Walle, M. DeLegge, Faye Hsieh, 2004, Drug Metabolism and Disposition.

Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors.

E. Lobenhofer, Kristin L. Andrews, B. Herberich, 2015, ACS medicinal chemistry letters.

Glucuronidation versus oxidation of the flavonoid galangin by human liver microsomes and hepatocytes.

T. Walle, Faye Hsieh, Y. Otake, 2002, Drug metabolism and disposition: the biological fate of chemicals.

The optimization of aminooxadiazoles as orally active inhibitors of Cdc7.

T. Bush, M. Rong, K. Sham, 2013, Bioorganic & medicinal chemistry letters.

Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.

P. Gallant, A. Oliveira-dos-Santos, J. Newcomb, 2008, Journal of medicinal chemistry.

Discovery of novel 2,3-diarylfuro[2,3-b]pyridin-4-amines as potent and selective inhibitors of Lck: synthesis, SAR, and pharmacokinetic properties.

J. Newcomb, Xin Huang, Steve Schneider, 2007, Bioorganic & medicinal chemistry letters.

Discovery of pyridazinopyridinones as potent and selective p38 mitogen-activated protein kinase inhibitors.

Matthew R. Lee, A. Tasker, Bin Wu, 2010, Journal of medicinal chemistry.

Identification of triazolopyridazinones as potent p38α inhibitors.

S. Chmait, B. Herberich, Matthew R. Lee, 2012, Bioorganic & medicinal chemistry letters.

Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.

S. Chmait, K. Miner, Matthew R. Lee, 2010, Bioorganic & medicinal chemistry letters.

Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase.

Christopher Mohr, Lisa Sherman, S. Chmait, 2010, Journal of medicinal chemistry.

Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.

P. Gallant, A. Oliveira-dos-Santos, J. Newcomb, 2008, Journal of medicinal chemistry.

Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.

Xin Huang, David Powers, Daniela Metz, 2006, Journal of medicinal chemistry.

Solid-phase synthesis and structure-activity relationships of novel biarylethers as melanin-concentrating hormone receptor-1 antagonists.

C. Hulme, A. Bannon, J. Salon, 2006, Bioorganic & medicinal chemistry letters.

Discovery of highly selective and potent p38 inhibitors based on a phthalazine scaffold.

R. Syed, B. Herberich, Matthew R. Lee, 2008, Journal of medicinal chemistry.

3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.

R. Syed, Matthew R. Lee, A. Tasker, 2008, Journal of medicinal chemistry.

Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.

S. Chmait, K. Miner, Matthew R. Lee, 2009, Bioorganic & medicinal chemistry letters.

Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as inhibitors of Lck: development of an expedient and divergent synthetic route and preliminary SAR.

A. Cheng, J. Newcomb, Xin Huang, 2007, Bioorganic & medicinal chemistry letters.

Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity.

P. Gallant, M. Morrison, D. Elbaum, 2006, Journal of medicinal chemistry.